Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Nat Rev Rheumatol ; 19(6): 378-393, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-37161084

RESUMEN

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and granulomatous or vasculitic involvement of several organs. The diagnosis and management of EGPA are often challenging and require an integrated, multidisciplinary approach. Current practice relies on recommendations and guidelines addressing the management of ANCA-associated vasculitis and not specifically developed for EGPA. Here, we present evidence-based, cross-discipline guidelines for the diagnosis and management of EGPA that reflect the substantial advances that have been made in the past few years in understanding the pathogenesis, clinical subphenotypes and differential diagnosis of the disease, as well as the availability of new treatment options. Developed by a panel of European experts on the basis of literature reviews and, where appropriate, expert opinion, the 16 statements and five overarching principles cover the diagnosis and staging, treatment, outcome and follow-up of EGPA. These recommendations are primarily intended to be used by healthcare professionals, pharmaceutical industries and drug regulatory authorities, to guide clinical practice and decision-making in EGPA. These guidelines are not intended to limit access to medications by healthcare agencies, nor to impose a fixed order on medication use.


Asunto(s)
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos , Síndrome de Churg-Strauss , Granulomatosis con Poliangitis , Humanos , Granulomatosis con Poliangitis/diagnóstico , Granulomatosis con Poliangitis/tratamiento farmacológico , Síndrome de Churg-Strauss/diagnóstico , Síndrome de Churg-Strauss/tratamiento farmacológico , Diagnóstico Diferencial , Anticuerpos Anticitoplasma de Neutrófilos
2.
Eur J Clin Invest ; 46(8): 690-7, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27314629

RESUMEN

BACKGROUND: Atherosclerosis is a pro-inflammatory condition, in which leucocyte activation plays an important role. The interaction between circulating leucocytes and apolipoprotein (apo) B-containing lipoproteins results in pro-inflammatory changes of these cells. We aimed to evaluate the relationship between apo B bound to circulating leucocytes and atherosclerosis. METHODS: Apo B on circulating leucocytes was measured by flow cytometry in subjects with and without cardiovascular disease (CVD), expressed as mean fluorescent intensity in arbitrary units (au). Carotid intima-media thickness (cIMT) was measured using B-mode ultrasound. Data are given as median (interquartile range). RESULTS: A total of 396 subjects were included, of whom 183 had a history of CVD. Compared to subjects without CVD, patients with CVD had lower apo B bound to neutrophils (12·7 au (9·8-16·2) and 14·2 au (10·1-17·5), respectively, P = 0·038) and to monocytes (2·5 au (1·7-3·1) and 2·7 (1·9-3·6) au, respectively, P = 0·025). No differences were found for lymphocyte-bound apo B. Neutrophil- and monocyte-bound apo B were inversely correlated with cIMT (Spearman's rho: -0·123, P = 0·017 and -0·108, P = 0·035, respectively). Both monocyte- and neutrophil-bound apo B were inversely associated with different factors related to the metabolic syndrome, such as body mass index, triglycerides and complement C3. There was a positive association between erythrocyte-bound apo B and apo B bound to each of the leucocyte classes, possibly reflecting a similar mechanism. Discontinuation of statins in 54 subjects did not influence leucocyte-bound apo B. CONCLUSION: Unexpectedly, the presence of noninternalized apo B-containing lipoproteins on circulating neutrophil and monocyte membranes may represent a protective mechanism against atherosclerosis.


Asunto(s)
Apolipoproteínas B/metabolismo , Aterosclerosis/etiología , Leucocitos/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Aterosclerosis/tratamiento farmacológico , Grosor Intima-Media Carotídeo , Estudios Transversales , Femenino , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Masculino , Persona de Mediana Edad , Neutrófilos/metabolismo , Factores de Riesgo , Adulto Joven
4.
Int J Hyg Environ Health ; 217(4-5): 586-91, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24332681

RESUMEN

Exposure to silica dust has been examined as a possible risk factor for autoimmune diseases, including systemic sclerosis, rheumatoid arthritis, systemic lupus erythematosus and ANCA-associated vasculitis. However, the underlying cellular and molecular mechanisms resulting in the increased prevalence of autoimmunity remain elusive. To clarify these mechanisms, we studied various markers of immune activation in individuals occupationally exposed to silica dust, i.e., serum levels of soluble IL-2 receptor (sIL-2R), levels of IL-2, other pro- and anti-inflammatory cytokines and lymphoproliferation. Our results demonstrate that silica-exposed individuals present important alterations in their immune response when compared to controls, as shown by increased serum sIL-2R levels, decreased production of IL-2 and increased levels of the pro-inflammatory (IFN-γ, IL-1α, TNF-α, IL-6) as well as anti-inflammatory (IL-10 and TGF-ß) cytokines. Furthermore, silica-exposed individuals presented enhanced lymphoproliferative responses. Our findings provide evidence that the maintenance of immune homeostasis may be disturbed in silica-exposed individuals, possibly resulting in autoimmune disorders.


Asunto(s)
Contaminantes Ambientales/toxicidad , Activación de Linfocitos , Exposición Profesional , Dióxido de Silicio/toxicidad , Anciano , Brasil , Proliferación Celular , Femenino , Humanos , Interleucina-2/metabolismo , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/efectos de los fármacos , Masculino , Persona de Mediana Edad , Receptores de Interleucina-2/sangre
6.
PLoS One ; 8(2): e57815, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23469072

RESUMEN

Transient activation of the renin-angiotensin system (RAS) induces irreversible renal damage causing sustained elevation in blood pressure (BP) in Cyp1a1-Ren2 transgenic rats. In our current study we hypothesized that activation of the AT1-receptor (AT1R) leads to a T-cell response causing irreversible impairment of renal function and hypertension. Cyp1a1-Ren2 rats harbor a construct for activation of the RAS by indole-3-carbinol (I3C). Rats were fed a I3C diet between 4-8 weeks of age to induce hypertension. Next, I3C was withdrawn and rats were followed-up for another 12 weeks. Additional groups received losartan (20 mg/kg/day) or hydralazine (100 mg/kg/day) treatment between 4-8 weeks. Rats were placed for 24h in metabolic cages before determining BP at week 8, 12 and 20. At these ages, subsets of animals were sacrificed and the presence of kidney T-cell subpopulations was investigated by immunohistochemistry and molecular marker analysis. The development of sustained hypertension was completely prevented by losartan, whereas hydralazine only caused a partial decrease in BP. Markers of renal damage: KIM-1 and osteopontin were highly expressed in urine and kidney samples of I3C-treated rats, even until 20 weeks of age. Additionally, renal expression of regulatory-T cells (Tregs) was highly increased in I3C-treated rats, whereas the expression of T-helper 1 (Th1) cells demonstrated a strong decrease. Losartan prevented these effects completely, whereas hydralazine was unable to affect these changes. In young Cyp1a1-Ren2 rats AT1R activation leads to induction of an immune response, causing a shift from Th1-cells to Tregs, contributing to the development of irreversible renal damage and hypertension.


Asunto(s)
Riñón/patología , Riñón/fisiopatología , Receptor de Angiotensina Tipo 1/metabolismo , Sistema Renina-Angiotensina/inmunología , Animales , Biomarcadores/metabolismo , Hemodinámica/efectos de los fármacos , Hidralazina/farmacología , Hipertensión/inmunología , Hipertensión/metabolismo , Hipertensión/patología , Hipertensión/fisiopatología , Riñón/efectos de los fármacos , Riñón/metabolismo , Losartán/farmacología , Ratas , Ratas Transgénicas , Sistema Renina-Angiotensina/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Factores de Tiempo
7.
Int J Hyg Environ Health ; 215(6): 562-9, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22153879

RESUMEN

Exposure to silica dust has been examined as a possible risk factor for autoimmune diseases, including scleroderma, rheumatoid arthritis and systemic lupus erythematosus. Since CTLA-4 [CD152] and PD-1 [CD279] are important for the maintenance of peripheral tolerance by regulating T cell responsiveness, we evaluated the expression of these molecules on the surface of CD4 and CD8 T cells, as well as single nucleotide polymorphisms (SNP) in CTLA-4 and PDCD1 genes, of 70 silica-exposed workers and 30 non-exposed, age-, ethnically- and sex-matched controls. Expression of CTLA-4 was significantly (P<0.05) reduced in CD4 T cells of exposed individuals [median=0.1% and interquartile range, IQR 0.0-0.1% (exposed), median=0.20%, IQR 0.0-0.4% (control)]. Also the expression of PD-1 was significantly (P<0.0001) reduced in both CD4 [median=0.9%, IQR 0.4-2.3% (exposed), median=5.7%, IQR 1.4-13.3% (control)] and CD8 T cells [median=0.9%, IQR 0.3-1.9% (exposed), median=5.0%, IQR 3.4-8.9% (control)]. The study of polymorphisms demonstrated a lower frequency of the A allele in the analysis of the PD1.3 SNP in the exposed group, which might be associated with the lower expression of PD-1 on the surface of CD4 T cells. Our findings provide evidence for the association of silica exposure and the maintenance of self-tolerance, i.e., the susceptibility to autoimmune disorders.


Asunto(s)
Antígeno CTLA-4/genética , Exposición Profesional , Receptor de Muerte Celular Programada 1/genética , Dióxido de Silicio/inmunología , Linfocitos T/metabolismo , Anciano , Recuento de Linfocito CD4 , Antígeno CTLA-4/metabolismo , Estudios de Casos y Controles , Femenino , Citometría de Flujo , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Receptor de Muerte Celular Programada 1/metabolismo
8.
Obesity (Silver Spring) ; 19(8): 1690-8, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21253003

RESUMEN

Abdominal fat-related activation of the innate immune system and insulin resistance (IR) are implicated in the pathogenesis of cardiovascular diseases. Recent data support an important role of the adaptive immune system as well. In this study, we investigate the association between waist circumference and markers of systemic adaptive immune activation, and the potential mediating role of innate immune activation and/or IR herein. The study population consisted of 477 (304 men) individuals (mean age: 59.4 ± 7.0 years) in whom waist circumference, HOMA2-IR (IR derived from homeostasis model assessment), and markers of innate (C-reactive protein (CRP), interleukin (IL)-6, serum amyloid A (SAA)) and adaptive (neopterin, soluble CD25 (sCD25)) immune activation were measured. These markers were compiled into an adaptive and innate immune activation score by averaging the respective z-scores. After adjustments for age, sex, glucose metabolism, smoking status, prior cardiovascular disease, and other risk factors, waist circumference was associated with the adaptive (standardized regression coefficient ß = 0.12 (95% confidence intervals: 0.04-0.20)) and the innate immune activation scores (ß = 0.24 (0.17-0.31)), and with HOMA2-IR (ß = 0.49 (0.42-0.56)). The innate immune activation score and HOMA2-IR were also positively associated with the adaptive immune activation score (ß = 0.31 (0.21-0.40) and ß = 0.11 (0.02-0.21), respectively). The association between waist circumference and the adaptive immune activation score was completely abolished when further adjusted for innate immune activation and HOMA2-IR (to ß = -0.01 (-0.10-0.08)), and the specific mediation "effects" attributable to each of these variables were 58% and 42%, respectively. We conclude that abdominal obesity is associated with systemic adaptive immune activation and that innate immune activation and IR constitute independent and equally important pathways explaining this association.


Asunto(s)
Grasa Abdominal/inmunología , Inmunidad Adaptativa , Enfermedades Cardiovasculares/etiología , Inmunidad Innata , Resistencia a la Insulina , Obesidad Abdominal/inmunología , Circunferencia de la Cintura/inmunología , Anciano , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Femenino , Humanos , Subunidad alfa del Receptor de Interleucina-2/sangre , Interleucina-6/sangre , Masculino , Persona de Mediana Edad , Neopterin/sangre , Obesidad Abdominal/sangre , Obesidad Abdominal/complicaciones , Proteína Amiloide A Sérica/metabolismo
9.
Rheumatology (Oxford) ; 48(6): 622-5, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19336578

RESUMEN

OBJECTIVES: As the HLA system is involved in recognition of self and non-self, an association with the development of ANCA-associated vasculitis (AAV) seems probable. In this study, the relation between HLA antigens and AAV and it's severity were investigated. METHODS: Consecutive patients diagnosed with AAV at our centre, who were followed for at least 2 years, were included. The frequency of HLA antigens of AAV and WG patients was compared with 5872 healthy blood donors from the same region and with 4000 healthy Dutch controls originating from a Eurotransplant database. RESULTS: From 304 AAV patients, sufficient data were available. We found DR13(6) to be less prevalent and both DR4 and the ancestral haplotype A1B8DR3 more prevalent in patients with AAV compared with controls, particularly in patients with WG. In addition, DR1 was less prevalent in patients with WG in comparison with controls. Further, DR8 was more prevalent in patients with CSS compared with other forms of vasculitis and controls. There were no associations between HLA antigens and disease characteristics or course of AAV or WG. CONCLUSIONS: AAV is associated with increased prevalence of DR4 and the ancestral haplotype A1B8DR3 and with decreased prevalence of DR13(6), particularly in patients with WG. In patients with WG, prevalence of DR1 was decreased, whereas in patients with CSS DR8 was increased. No associations between HLA antigens and disease characteristics or course of AAV were found.


Asunto(s)
Anticuerpos Anticitoplasma de Neutrófilos/inmunología , Antígenos HLA/genética , Vasculitis/genética , Vasculitis/inmunología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Supervivencia sin Enfermedad , Femenino , Predisposición Genética a la Enfermedad , Genotipo , Granulomatosis con Poliangitis/genética , Granulomatosis con Poliangitis/inmunología , Antígeno HLA-A1/genética , Antígeno HLA-B8/genética , Antígenos HLA-DR/genética , Subtipos Serológicos HLA-DR , Antígeno HLA-DR3/genética , Antígeno HLA-DR4/genética , Haplotipos , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Serotipificación , Índice de Severidad de la Enfermedad , Estadísticas no Paramétricas , Adulto Joven
10.
Eur J Heart Fail ; 11(2): 119-29, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19168509

RESUMEN

The increasing prevalence of heart failure poses enormous challenges for health care systems worldwide. Despite effective medical interventions that target neurohumoral activation, mortality and morbidity remain substantial. Evidence for inflammatory activation as an important pathway in disease progression in chronic heart failure has emerged in the last two decades. However, clinical trials of 'anti-inflammatory' therapies (such as anti-tumor necrosis factor-alpha approaches) have to date failed to show benefit in heart failure patients. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop to address the issue of inflammation in heart failure from a basic science, translational and clinical perspective, and to assess whether specific inflammatory pathways may yet serve as novel therapeutic targets for this condition. This consensus document represents the outcome of the workshop and defines key research questions that still need to be addressed as well as considering the requirements for future clinical trials in this area.


Asunto(s)
Antiinflamatorios/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Animales , Antioxidantes/uso terapéutico , Proteína C-Reactiva/uso terapéutico , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/metabolismo , Humanos , Factores Inmunológicos/uso terapéutico , Inflamación , Lectina de Unión a Manosa/metabolismo , Inhibidores de la Metaloproteinasa de la Matriz , Inhibidores de las Quinasa Fosfoinosítidos-3 , Componente Amiloide P Sérico/uso terapéutico
11.
Ann Rheum Dis ; 66(2): 222-7, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16901958

RESUMEN

BACKGROUND: The classification of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and polyarteritis nodosa (PAN) for epidemiology studies is confusing. The existing schemes such as American College of Rheumatology (ACR) criteria, Chapel Hill Consensus Conference (CHCC) definitions and Lanham criteria produce overlapping and conflicting classifications, making it difficult to compare incidence figures. AIM: To develop a consensus method of using these criteria and definitions for epidemiological studies to permit comparison without confounding by classification. METHODS: A stepwise algorithm was developed by consensus between a group of doctors interested in the epidemiology of vasculitis. The aim was to categorise patients with Wegener's granulomatosis, microscopic polyangiitis (MPA), Churg-Strauss syndrome (CSS) and PAN into single clinically relevant categories. The ACR and Lanham criteria for CSS, and ACR criteria for Wegener's granulomatosis were applied first, as these were considered to be the most specific. Surrogate markers for Wegener's granulomatosis were included to distinguish Wegener's granulomatosis from MPA. MPA was classified using the CHCC definition and surrogate markers for renal vasculitis. Finally, PAN was classified using the CHCC definition. The algorithm was validated by application to 20 cases from each centre and 99 from a single centre, followed by a paper case exercise. RESULTS: A four-step algorithm was devised. It successfully categorises patients into a single classification. There was good correlation between observers in the paper case exercise (91.5%; unweighted kappa = 0.886). CONCLUSION: The algorithm achieves its aim of reliably classifying patients into a single category. The use of the algorithm in epidemiology studies should permit comparison between geographical areas.


Asunto(s)
Algoritmos , Anticuerpos Anticitoplasma de Neutrófilos/sangre , Poliarteritis Nudosa/clasificación , Vasculitis/clasificación , Biomarcadores/sangre , Síndrome de Churg-Strauss/clasificación , Granulomatosis con Poliangitis/clasificación , Humanos , Poliarteritis Nudosa/epidemiología , Poliarteritis Nudosa/inmunología , Vasculitis/epidemiología , Vasculitis/inmunología
13.
Eur J Intern Med ; 14(5): 296-301, 2003 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-13678754

RESUMEN

BACKGROUND: Previously, we demonstrated that the number of polymorphonuclear neutrophils (PMNs) in bronchoalveolar lavage fluid (BALF) is useful in distinguishing sarcoidosis patients with a favorable outcome from those having a more severe course of disease. Neutrophils contain the oxidant-generating enzyme myeloperoxidase (MPO). Cellular levels of MPO can be influenced by functional promotor polymorphisms, ?463G/A and ?129G/A, which may modify disease severity. METHODS: In the present study, we investigated two MPO promotor polymorphisms in 110 sarcoidosis patients and in 191 ethnically matched controls. Pulmonary disease severity was evaluated by means of radiographic staging, HRCT scoring, lung function, and exercise capacity testing. RESULTS: No significant differences were found between sarcoidosis patients and healthy controls with regard to either polymorphism. Nor was any association observed between ?463 G/A and ?129 G/A polymorphism and the severity of sarcoidosis. CONCLUSIONS: The functional MPO promotor polymorphisms ?463G/A and ?129G/A did not explain disease severity in the sarcoidosis population studied. Future studies are needed to identify predictive features useful in guiding therapeutic strategies and to determine difficult-to-treat cases.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA